Whether youre interested in trying weight loss medication, mulling over the idea of joining a commercial weight loss plan or are interested in combining the two, your first stop should be your doctors office
Danuglipron (dosed twice daily) and orforglipron (once daily) continue in clinical trials, while the clinical development of lotiglipron (once daily) was recently stopped due to elevated transaminase liver enzymes
It also improved cardiac activity, as seen by echocardiography (Wang et al., 2016)
Researchers documented these milestones in uncovering the vision risks: Summer 2023: Three NAION cases presented at Mass Eye and Ear within a short period, all involving semaglutide users July 2024: Publication of the landmark Harvard study in JAMA Ophthalmology revealing increased NAION risk December 2024: Danish researchers published supporting studies involving over 424,000 patients 2025: Multiple international studies confirmed the association between semaglutide and vision problems The pivotal Harvard study analyzed medical records from 16,827 patients treated between 2017 and 2023, comparing those prescribed semaglutide against patients using other diabetes or weight loss medications
However, if you have any serious side effects you should talk to your prescriber as soon as possible to discuss whether to lower your dose
